RELATED STUDY

Cannabis compounds exhibit anti-inflammatory activity in vitro in COVID-19-related inflammation in lung epithelial cells and pro-inflammatory activity in macrophages

Key Findings:  CBD, CBG and THCV may have clinical value in reducing cytokine secretion in lung epithelial cell however, an extract of a cannabis chemotype III (abundant in CBD) containing various terpenes increased pro-inflammatory cytokine production. As such the authors posit that, that for now, cannabinoid-based therapeutics ought to be avoided in the treatment or prevention of COVID-19.